{
    "clinical_study": {
        "@rank": "70608", 
        "arm_group": [
            {
                "arm_group_label": "500 Units First, Then 1000 Units", 
                "arm_group_type": "Experimental", 
                "description": "500 Units of CINRYZE administered by IV injection twice per week for 12 weeks followed by 1000 Units of CINRYZE administered by IV injection twice per week for 12 weeks"
            }, 
            {
                "arm_group_label": "1000 Units First, Then 500 Units", 
                "arm_group_type": "Experimental", 
                "description": "1000 Units of CINRYZE administered by IV injection twice per week for 12 weeks followed by 500 Units of CINRYZE administered by IV injection twice per week for 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objective - To assess the relative efficacy of two dose levels of CINRYZE (500 Units\n      and 1000 Units) administered by intravenous (IV) injection every 3 or 4 days to prevent\n      angioedema attacks in children 6 to 11 years of age with hereditary angioedema (HAE).\n\n      Secondary Objectives - To assess the safety and tolerability, characterize the\n      pharmacokinetics (PK) and pharmacodynamics (PD), and assess the immunogenicity of two dose\n      levels of CINRYZE administered by IV injection in children 6 to 11 years of age with HAE."
        }, 
        "brief_title": "Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hereditary Angioedema", 
        "condition_browse": {
            "mesh_term": [
                "Angioedema", 
                "Angioedemas, Hereditary"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of Type I or Type II HAE.\n\n          -  History of angioedema attacks.\n\n        Exclusion Criteria:\n\n          -  History of bleeding or clotting abnormality.\n\n          -  Diagnosis of acquired angioedema or known to have C1 INH antibodies.\n\n          -  History of allergic reaction to C1 esterase inhibitor or other blood products.\n\n          -  Receipt of any experimental agents other than those required for prevention or\n             treatment of angioedema attacks within 30 days prior to screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "11 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02052141", 
            "org_study_id": "0624-301"
        }, 
        "intervention": {
            "arm_group_label": [
                "500 Units First, Then 1000 Units", 
                "1000 Units First, Then 500 Units"
            ], 
            "intervention_name": "CINRYZE", 
            "intervention_type": "Biological", 
            "other_name": "C1 esterase inhibitor (human)"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Complement C1 Inactivator Proteins", 
                "Complement C1 Inhibitor Protein", 
                "Complement C1", 
                "Complement C1s"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pediatric", 
            "HAE", 
            "Cinryze", 
            "C1 inhibitor", 
            "C1 INH", 
            "Prevention"
        ], 
        "lastchanged_date": "March 19, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "ViroPharma Clinical Operations", 
                    "phone": "866-331-5637"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "ViroPharma Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "ViroPharma Clinical Operations", 
                    "phone": "866-331-5637"
                }, 
                "facility": {
                    "address": {
                        "city": "Santa Monica", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90404"
                    }, 
                    "name": "ViroPharma Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "ViroPharma Clinical Operations", 
                    "phone": "866-331-5637"
                }, 
                "facility": {
                    "address": {
                        "city": "Colorado Springs", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80907"
                    }, 
                    "name": "ViroPharma Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "ViroPharma Clinical Operations", 
                    "phone": "866-331-5637"
                }, 
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "89106"
                    }, 
                    "name": "ViroPharma Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "ViroPharma Clinical Operations", 
                    "phone": "866-331-5637"
                }, 
                "facility": {
                    "address": {
                        "city": "Eugene", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97401"
                    }, 
                    "name": "ViroPharma Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "ViroPharma Clinical Operations", 
                    "phone": "866-331-5637"
                }, 
                "facility": {
                    "address": {
                        "city": "Spokane", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "99204"
                    }, 
                    "name": "ViroPharma Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "ViroPharma Clinical Operations", 
                    "phone": "+1 866-331-5637"
                }, 
                "facility": {
                    "address": {
                        "city": "Buenos Aires", 
                        "country": "Argentina", 
                        "zip": "C1431FWN"
                    }, 
                    "name": "ViroPharma Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "ViroPharma Clinical Operations", 
                    "phone": "+32 2 747 09 71"
                }, 
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany", 
                        "zip": "60590"
                    }, 
                    "name": "ViroPharma Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "ViroPharma Clinical Operations", 
                    "phone": "+32 2 747 09 71"
                }, 
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany", 
                        "zip": "55131"
                    }, 
                    "name": "ViroPharma Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "ViroPharma Clinical Operations", 
                    "phone": "+32 2 747 09 71"
                }, 
                "facility": {
                    "address": {
                        "city": "M\u00f6rfelden-Walldorf", 
                        "country": "Germany", 
                        "zip": "64546"
                    }, 
                    "name": "ViroPharma Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "ViroPharma Clinical Operations", 
                    "phone": "+32 2 747 09 71"
                }, 
                "facility": {
                    "address": {
                        "city": "Salerno", 
                        "country": "Italy", 
                        "zip": "84131"
                    }, 
                    "name": "ViroPharma Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "ViroPharma Clinical Operations", 
                    "phone": "+1 866-331-5637"
                }, 
                "facility": {
                    "address": {
                        "city": "Mexico City", 
                        "country": "Mexico", 
                        "zip": "04530"
                    }, 
                    "name": "ViroPharma Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "ViroPharma Clinical Operations", 
                    "phone": "+32 2 747 09 71"
                }, 
                "facility": {
                    "address": {
                        "city": "Targu-Mures", 
                        "country": "Romania", 
                        "zip": "540072"
                    }, 
                    "name": "ViroPharma Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "ViroPharma Clinical Operations", 
                    "phone": "+32 2 747 09 71"
                }, 
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom", 
                        "zip": "M13 9WL"
                    }, 
                    "name": "ViroPharma Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Argentina", 
                "Germany", 
                "Italy", 
                "Mexico", 
                "Romania", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3, Multicenter, Randomized, Single-Blind, Dose-Ranging, Crossover Study to Evaluate the Safety and Efficacy of Intravenous Administration of CINRYZE\u00ae (C1 Esterase Inhibitor [Human]) for the Prevention of Angioedema Attacks in Children 6 to 11 Years of Age With Hereditary Angioedema", 
        "overall_official": {
            "affiliation": "ViroPharma", 
            "last_name": "Martino Laurenzi, MD, MPH", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Germany: Paul-Ehrlich-Institut", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Italy: The Italian Medicines Agency", 
                "Romania: National Agency for Medicines and Medical Devices", 
                "Mexico: Federal Commission for Protection Against Health Risks", 
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of angioedema attacks in each treatment period", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02052141"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of subjects with adverse events by dose group", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change from baseline in C1 inhibitor (C1 INH) and C4 concentrations during each treatment period", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose to 1 hour post-dose at Visit 1, Week 6, and Week 12"
            }, 
            {
                "measure": "Number of subjects with C1 INH antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "28 weeks"
            }
        ], 
        "source": "Shire", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shire", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}